trial

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

NCTId NCT05064319
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 68 (estimated)
Sponsored by Medical University of South Carolina
Primary completion 2026-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
68 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2022-02-24
Primary completion
2026-06-30
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Gabapentin

Sponsors

Medical University of South CarolinaLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator

Investigators

1
James J Prisciandaro, PhDPrincipal Investigator

Sites

1 total
Charleston, United States

Linked catalysts

1
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and — primary completion2026-06-30

Facts & assertions

4 sourced
Enrollment
68
Phase
PHASE2
Primary Completion Date
2026-06-30
Status
RECRUITING
relationships
The graph out of here
drug
Gabapentin
drug
lead_sponsor
Medical University of South Carolina
company
collaborator
National Institute on Drug Abuse (NIDA)
company
indication
Lymphoma, Follicular
indication
Bipolar Disorder
indication
Bipolar I Disorder
indication
investigator
James J Prisciandaro, PhD
person